William Andrew Bonner

US Patent:

6362317, Mar 26, 2002

Filed:

Jul 12, 1999

Appl. No.:

09/351721

Inventors:

William M. Bonner - Potomac MD
Emmy Rogakou - Bethesda MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C07K 1618

US Classification:

5303871, 530358

Abstract:

The present invention provides an isolated or purified antibody or antigenically-reactive fragment thereof that specifically binds to a C-terminal phosphorylated serine in an H2A histone protein and a product comprising the same. The present invention further provides fusion proteins comprising the isolated or purified antibody or antigenically-reactive fragment thereof. Also provided by the present invention are a method and a kit for determining double-stranded breaks in DNA. The method comprises contacting a sample comprising H2A histone proteins with the isolated or purified antibody or antigenically-reactive fragment thereof and detecting binding of the antibody or fragment thereof to an H2A histone protein in the sample. The detection of the binding of the antibody or fragment thereof to the H2A histone protein indicates the presence of a DNA double-stranded break in DNA.

US Patent:

6884873, Apr 26, 2005

Filed:

Nov 7, 2001

Appl. No.:

10/045720

Inventors:

William M. Bonner - Potomac MD, US
Emmy Rogakou - Bethesda MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C07K016/18
C07K014/435

US Classification:

5303871, 530358, 530350, 5303879, 5303881, 5303891, 435328

Abstract:

The present invention provides an isolated or purified antibody or antigenically-reactive fragment thereof that specifically binds to a C-terminal phosphorylated serine in an H2A histone protein and a product comprising the same. The present invention further provides fusion proteins comprising the isolated or purified antibody or antigenically-reactive fragment thereof. Also provided by the present invention are a method and a kit for determining double-stranded breaks in DNA. The method comprises contacting a sample comprising H2A histone proteins with the isolated or purified antibody or antigenically-reactive fragment thereof and detecting binding of the antibody or fragment thereof to an H2A histone protein in the sample. The detection of the binding of the antibody or fragment thereof to the H2A histone protein indicates the presence of a DNA double-stranded break in DNA.

US Patent:

20180003720, Jan 4, 2018

Filed:

Feb 1, 2016

Appl. No.:

15/545402

Inventors:

- Bethesda MD, US
William M. Bonner - Washington DC, US
Yiping Zhang - Boyds MD, US
Jiuping Ji - Rockville MD, US

Assignee:

The United States of America,as represented by the Secretary,Department of Health and Human Service - Bethesda MD

International Classification:

G01N 33/68
C12Q 1/68

Abstract:

Disclosed are methods of measuring the amount of exposure of a host to a DNA double-stranded break (DSB)-causing agent by determining the ratio of the quantity of γ-H2AX to the quantity of total H2AX in a biological sample from the host as compared to the ratio of the quantity of γ-H2AX to the quantity of total H2AX in a positive control biological sample that has been exposed to a known amount of a DSB-causing agent. Related kits and methods of quantifying DSBs in a test biological sample are also disclosed.